Maintaining muscle mass has proven to be crucial for patients undergoing cancer treatment. Studies have shown that ...

Gilead Sciences' TROP2-targeting drug Trodelvy is already used as a third-line treatment for PD-L1-positive triple-negative ...

Oklahoma lawmakers overrode Governor Stitt's veto on a bill enhancing access to advanced breast cancer screenings, ensuring ...

A clinical trial found that women could switch drugs without waiting for scans showing cancer progression, which improved ...

First-line treatment with sacituzumab govitecan plus pembrolizumab showed significant improvement in PFS vs. chemotherapy ...

Camizestrant plus CDK4/6 inhibition improved progression-free survival when given to patients with ESR1-mutant ER+/HER2– ...

CK Wang, MD, explains that Black women face higher rates of late-stage breast and ovarian cancer diagnoses, demonstrating the ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Data presented at ASCO show that swapping in the oral drug camizestrant for an older therapy helped sustain the benefit of ...

Approximately 70% of breast cancers are HR-positive/HER2 negative. While activating ESR1 mutations are rare at the time of ...

AstraZeneca Plc’s experimental breast cancer pill delayed disease progression by over six months, according to data from a ...

A new drug can help stop certain breast cancer tumours before they grow, experts say. A trial called Serena-6 shows that ...